Overview

Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects

Status:
COMPLETED
Trial end date:
2025-02-27
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the efficacy of ROSE-010 on food intake in female subjects with overweight and obesity. The secondary objectives of this study are the following: * To assess the efficacy of ROSE-010 on hunger; * To assess the efficacy of ROSE-010 on satiety; * To assess the efficacy of ROSE-010 on prospective consumption; * To assess the efficacy of ROSE-010 on desire to eat; * To assess the efficacy of ROSE-010 on palatability; * To characterize the pharmacokinetics (PK) of ROSE-010 following subcutaneous (SC) administration on Day 1 and Day 7; and * To evaluate safety and tolerability of SC administrations of ROSE-010 to overweight and obese subjects.
Phase:
PHASE2
Details
Lead Sponsor:
Rose Pharma Inc
Treatments:
glucagon-like peptide (7-37), valyl(10)-